HPV Genotyping Test for Cervical Cancer at Chughtai Lab

HPV Genotyping at Chughtai Lab

Human Papillomavirus (HPV) is one of the most common sexually transmitted infections globally, with specific high-risk genotypes directly linked to the development of cervical, vulvar, vaginal, anal, and oropharyngeal cancers. HPV Genotyping at Chughtai Lab is a highly sophisticated molecular diagnostic test designed to identify the specific genetic strains of HPV present in a patient’s sample. Unlike basic screening tests that merely indicate the presence of the virus, genotyping distinguishes between high-risk and low-risk strains. This distinction is clinically vital, as high-risk strains like HPV 16 and HPV 18 are responsible for approximately 70% of all cervical cancer cases worldwide. By utilizing advanced Polymerase Chain Reaction (PCR) technology, Chughtai Lab provides clinicians across Pakistan with the precise molecular data required to stratify patient risk, implement appropriate surveillance protocols, and make informed decisions regarding therapeutic interventions.

The clinical importance of HPV genotyping cannot be overstated. Cervical cancer is highly preventable if precancerous changes are detected and managed early. HPV genotyping acts as a primary screening tool or as a co-test alongside a traditional Liquid-Based Cytology (LBC) Pap smear. The test works by extracting viral DNA from cervical or mucosal cells and amplifying specific target regions of the HPV genome. This allows for the identification of individual high-risk genotypes (such as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) as well as low-risk genotypes (such as 6 and 11) which are primarily associated with benign genital warts. The diagnostic value of this test lies in its high sensitivity and negative predictive value, giving patients and healthcare providers peace of mind and a clear clinical pathway forward.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest accuracy and prevent sample contamination or inadequate cellular yield, patients must adhere to specific preparation guidelines prior to undergoing an HPV genotyping test at Chughtai Lab:

• Avoid scheduling the test during active menstruation, as excessive blood can interfere with molecular testing and cellular evaluation. The ideal time is 10 to 20 days after the first day of your last menstrual period.
• Do not use vaginal medications, contraceptive creams, spermicides, douches, or vaginal lubricants for at least 48 hours before the test, as these substances can interfere with viral DNA extraction.
• Refrain from sexual intercourse for 48 hours prior to specimen collection to prevent the introduction of foreign substances or cellular disruption.
• Inform your healthcare provider if you are pregnant, have had a recent pelvic examination, or have undergone any cervical procedures such as colposcopy, biopsy, or cryotherapy.

During the Procedure

The collection process for HPV genotyping is identical to a standard pelvic exam or Pap smear and is conducted in a private, comfortable environment by trained female medical professionals at Chughtai Lab:

• The patient is asked to undress from the waist down and lie on an examination table with feet placed in stirrups for optimal positioning.
• A sterile, lubricated speculum is gently inserted into the vagina to visualize the cervix clearly.
• The clinician uses a specialized, soft cervical brush (broom-like device) or cytobrush to collect cellular samples from both the ectocervix and endocervix (the transformation zone where most cervical pathologies originate).
• The brush is rotated gently to gather sufficient epithelial cells, which may cause a mild sensation of pressure or minor cramping.
• The collected sample is immediately placed into a vial containing liquid transport medium (Liquid-Based Cytology vial) to preserve the cellular and viral DNA.
• The speculum is carefully removed, and the procedure is complete, typically taking less than five minutes.
• The specimen is labeled with unique patient identifiers and transported to the molecular diagnostics department at Chughtai Lab under strict temperature-controlled conditions.

When is an HPV Genotyping Performed?

Abnormal Pap Smear Follow-Up

When a routine Pap smear reveals atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL), physicians request HPV genotyping. Identifying whether a high-risk HPV strain is driving these cellular changes helps determine if the patient requires immediate colposcopy or can safely return to routine surveillance.

Routine Cervical Cancer Screening

For women aged 30 to 65, medical guidelines recommend HPV genotyping either as a standalone primary screening test or as part of a co-testing regimen with a Pap smear. Because persistent high-risk HPV infection is the primary cause of cervical malignancies, screening helps identify women at risk long before physical cellular abnormalities manifest.

Evaluation of Genital Warts

Patients presenting with exophytic lesions or suspected condyloma acuminata (genital warts) undergo genotyping to confirm the diagnosis. While these lesions are typically caused by low-risk strains like HPV 6 and 11, genotyping ensures there is no co-infection with high-risk strains that could lead to neoplastic progression.

Monitoring Post-Treatment for CIN

Following therapeutic interventions for cervical intraepithelial neoplasia (CIN 2 or CIN 3), such as a Loop Electrosurgical Excision Procedure (LEEP) or cold knife cone biopsy, HPV genotyping is performed at scheduled intervals. Detecting the clearance or persistence of the specific pre-treatment HPV genotype helps clinicians assess the success of the treatment and monitor for recurrence.

Assessment of High-Risk Clinical Symptoms

Physicians order HPV genotyping for patients presenting with clinical symptoms suspicious of cervical pathology, such as unexplained post-coital bleeding, intermenstrual bleeding, persistent pelvic pain, or abnormal vaginal discharge. Genotyping helps rule out or confirm viral involvement as part of a comprehensive diagnostic workup.

What Does an HPV Genotyping Detect?

HPV genotyping is a highly specific molecular assay that detects the presence of viral DNA and identifies individual genotypes. The test is capable of detecting and distinguishing a wide array of viral strains, each associated with different levels of oncogenic risk:

• High-Risk Genotypes (Oncogenic): Detection of HPV 16 and HPV 18, which carry the highest risk of progression to cervical carcinoma. It also detects other high-risk strains including HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
• Low-Risk Genotypes (Non-Oncogenic): Detection of HPV 6 and HPV 11, which are responsible for benign laryngeal papillomas, oral papillomas, and genital warts.
• Co-Infections: Identification of multiple HPV genotypes within a single specimen, which is common in sexually active individuals and requires careful clinical monitoring.
• Specimen Adequacy: The assay includes an internal genomic control (such as human beta-globin DNA) to verify that a sufficient number of human cells were collected during the swab procedure, ensuring the validity of a negative result.
• Viral Persistence: When performed sequentially over several years, the test detects the persistence of the exact same viral genotype, which is the key driver of cervical carcinogenesis.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that waiting for diagnostic results can be an anxious time for patients. Because HPV genotyping involves highly complex molecular extraction, amplification, and sequencing protocols, the testing process requires specialized laboratory handling. Typically, the official report for HPV Genotyping at Chughtai Lab is completed and verified by a consultant pathologist within 3 to 5 working days from the time of sample collection.

Patients can access their reports easily and securely. Once the analysis is finalized, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be downloaded directly from the official Chughtai Lab website by entering the patient ID and case number. Additionally, patients can view, download, and archive their diagnostic history using the Chughtai Lab mobile application, or collect a printed copy from any of our conveniently located diagnostic centers across Pakistan.

HPV Genotyping Findings Overview

The following table outlines the clinical parameters evaluated during an HPV genotyping test, detailing normal findings and the clinical significance of abnormal results:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HPV 16 DNA	Not Detected (Negative)	Detected (Positive) – Indicates high risk for cervical intraepithelial neoplasia and cervical cancer.
HPV 18 DNA	Not Detected (Negative)	Detected (Positive) – Associated with aggressive cervical adenocarcinoma; requires close clinical follow-up.
Other High-Risk Genotypes	Not Detected (Negative)	Detected (Positive) for strains 31, 33, 45, 52, 58, etc. – Indicates elevated risk of cervical dysplasia.
Low-Risk Genotypes (6/11)	Not Detected (Negative)	Detected (Positive) – Associated with benign genital warts and low-grade cellular changes.
Internal Control (Cellular Adequacy)	Passed / Adequate	Failed / Inadequate – Indicates insufficient cellular material; requires a repeat sample collection.
Co-infection Status	No multiple strains detected	Multiple genotypes detected – Indicates exposure to several HPV strains; clinical management depends on the highest-risk strain.
Cytological Correlation	No abnormal cells (if co-tested)	Atypical cells (ASC-US, LSIL, HSIL) present alongside positive HPV DNA.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HPV Genotyping?

• Experienced Healthcare Professionals: Our molecular biology department is staffed by highly trained scientists and led by consultant pathologists specializing in molecular diagnostics.
• Patient-Focused Care: We prioritize patient comfort, privacy, and dignity, providing dedicated, private sample collection rooms for all gynecological and molecular swab procedures.
• Quality Diagnostic Services: Chughtai Lab adheres to rigorous international quality control standards, ensuring the highest level of accuracy and reproducibility for molecular testing.
• Professional Reporting: Our reports are comprehensive, clearly indicating the specific genotypes detected and their clinical risk categories to assist your physician in treatment planning.
• Modern Diagnostic Approach: We utilize state-of-the-art Real-Time PCR technology, which offers superior sensitivity and specificity compared to traditional screening methods.
• Comfortable Environment: Our diagnostic centers across Pakistan are designed to provide a clean, welcoming, and stress-free environment for all patients.
• Convenient Location: With an extensive network of collection centers in Lahore, Karachi, Islamabad, and throughout Pakistan, accessing our services is highly convenient.
• Commitment to Accurate Diagnosis: We employ strict sample tracking and barcoding protocols to eliminate pre-analytical errors, ensuring that every patient receives the correct, verified result.